Table 4.
Characteristic | Colon cancer patients that underwent adjuvant treatment | ||
---|---|---|---|
No myosteatosis, n = 31 | Myosteatosis, n = 63 | p value | |
Chemotherapy regimen | |||
5-FU plus oxaliplatin | 23 (82.1) | 36 (57.1) | 0.031 |
5-FU plus leucovorin | 5 (17.9) | 27 (42.9) | |
Adjuvant treatment complete, № (%) | 25 (80.7) | 35 (55.6) | 0.022 a |
Adjuvant treatment interrupted, № (%) | |||
Toxicity | 1 (3.2) | 17 (27.0) | 0.005 a |
Performance deterioration | 1 (3.3) | 2 (3.2) | 1.000 a |
Progression | 1 (3.2) | 4 (6.4) | 1.000 a |
Abandonment | 2 (6.3) | 4 (6.4) | 1.000 a |
NR | 1 (3.2) | 1 (1.6) | 1.000 a |
Toxicity grades III–IV, № (%) | |||
All | 12 (26.1) | 19 (39.6) | 0.164 a |
Diarrhea | 6 (19.4) | 18 (28.6) | 0.452 a |
Emesis | 2 (6.5) | 0 (0.0) | 0.116 a |
Mucositis | 3 (9.7) | 2 (3.2) | 0.327 a |
Hematological | 1 (3.2) | 11 (17.5) | 0.096 a |
Characteristic | Rectal cancer patients that underwent neoadjuvant treatment | ||
No myosteatosis, n = 36 | Myosteatosis, n = 50 | p value | |
5-FU or capecitabine plus radiotherapy, № (%) | 36 (100.0) | 50 (100.0) | 1.00 |
Neoadjuvant treatment complete, № (%) | 31 (86.1) | 48 (96.0) | 0.124 b |
Neoadjuvant treatment interrupted | 5 (13.9) | 2 (4.0) | |
Toxicity grades III–IV, № (%) | |||
All | 10 (27.8) | 16 (32.0) | 0.674 a |
Diarrhea | 6 (16.7) | 12 (24.0) | 0.592 a |
Emesis | 2 (5.6) | 1 (2.0) | 0.569 a |
Mucositis | 0 (0.0) | 2 (4.0) | 0.508 a |
Hematological | 2 (5.6) | 0 (0.0) | 0.172 a |
NR, not reported
Fisher’s exact test.
Chi-square test.